Login to Your Account

Right on 'Cue': Immunotherapy firm attracts $26M

By Marie Powers
News Editor

Tuesday, January 24, 2017

Cue Biopharma Inc. stepped into the bright lights of the I-O stage, adding a $16.4 million round to seed funding of $10 million to accelerate development of its platform of TCR biologics targeting cancer and autoimmune diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription